ArticleClinical and translational science2026
Real-World Evidence on Short-Term Weight Changes Following Methylphenidate Use in Pediatric Population: A Retrospective Study Using Common Data Model.
Article in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In July 2025, the Food and Drug Administration (FDA) warned of significant weight loss among young children receiving stimulants for attention-deficit hyperactivity disorder. However, real-world evidence on the magnitude and prevalence of stimulant-associated weight loss remains limited. This study evaluated short-term weight changes after methylphenidate initiation among youth aged 3-18 years using the Medical record Observation and Assessment of drug safety Common Data Model (MOA CDM) in Korea. We conducted a retrospective study using electronic health record-based MOA CDM data from January 2008 to December 2024. The cohort included individuals aged 3-18 years with at least one methylphenidate prescription and had available weight measurements. The index date was defined as the first prescription date. Individuals without weight data within 45 days before or 90 days after the index date were excluded. Outcomes included changes in body weight (kg) and weight percentile, and the proportion having a ≥ 10-percentile decline. Weight percentiles were calculated using the 2017 Korean National Growth Charts for Children and Adolescents. A total of 2087 youths from 17 nationwide hospitals were included; 68.71% were male, and 58.12% were aged 6-10 years. Within 3 months, mean body weight decreased by -0.33 kg (95% confidence interval [CI], -0.44 to -0.22) and mean weight percentile decreased by -2.49 percentiles (95% CI, -2.83 to -2.15). Overall, 21.57% had a ≥ 10 percentile decline, with larger reductions among pre-school-aged children (28.57%). Our findings underscores the importance of growth monitoring during treatment initiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.